ReviewArthritis care & research2026
Advancements in Diagnosis and Care for Immune Dysregulation and Inborn Errors of Immunity in Pediatric Rheumatology: Our 50-Year Journey.
Review in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Caring for children with complex immune disorders is part of the heritage of pediatric rheumatology that extends back to the original founders of the field. Over the past 50 years, pediatric rheumatologists have been central to advancing discovery and pioneering innovative treatment approaches for pediatric patients with multifaceted immune dysfunction. This includes dissecting disease mechanisms and identifying novel genes associated with inflammasome activation, IL-18 opathies, type I interferonopathies, monogenic mosaic disorders, and other forms of immune dysregulation. Pediatric rheumatologists have made foundational contributions to the management of patients with these conditions by leveraging their expertise in existing immunomodulatory medications and recognizing new drug targets. In the next 50 years, scientists and clinicians in the field are poised to make substantial innovations in understanding the causes and biomarkers of immune dysregulation. By harnessing the power of precision medicine, cellular therapies, and immune multidisciplinary teams, pediatric rheumatologists will continue to drive discoveries that will improve outcomes for patients with immune dysregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.